Literature DB >> 17671756

Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments.

Philip Wintermeyer1, Jack R Wands.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17671756     DOI： 10.1007/s00535-007-2057-5

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  98 in total

1.  Genetic immunization is a simple method for eliciting an immune response.

Authors:  D C Tang; M DeVit; S A Johnston
Journal:  Nature       Date:  1992-03-12       Impact factor: 49.962

2.  Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3.

Authors:  Hong Yu; Hui Huang; Jim Xiang; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  J Gen Virol       Date:  2006-01       Impact factor: 3.891

3.  Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells.

Authors:  N Bhardwaj; A Bender; N Gonzalez; L K Bui; M C Garrett; R M Steinman
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

4.  Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein.

Authors:  O Moriya; M Matsui; M Osorio; H Miyazawa; C M Rice; S M Feinstone; S H Leppla; J M Keith; T Akatsuka
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

5.  Direct gene transfer into mouse muscle in vivo.

Authors:  J A Wolff; R W Malone; P Williams; W Chong; G Acsadi; A Jani; P L Felgner
Journal:  Science       Date:  1990-03-23       Impact factor: 47.728

Review 6.  Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome.

Authors:  H J Alter; L B Seeff
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

7.  Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection.

Authors:  S Auffermann-Gretzinger; E B Keeffe; S Levy
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

8.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

Authors:  R Wang; D L Doolan; T P Le; R C Hedstrom; K M Coonan; Y Charoenvit; T R Jones; P Hobart; M Margalith; J Ng; W R Weiss; M Sedegah; C de Taisne; J A Norman; S L Hoffman
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

9.  Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection.

Authors:  Montserrat Puig; Marian E Major; Kathleen Mihalik; Stephen M Feinstone
Journal:  Vaccine       Date:  2004-02-25       Impact factor: 3.641

Review 10.  Genetic diversity and evolution of hepatitis C virus--15 years on.

Authors:  Peter Simmonds
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891
View more
  3 in total

1.  Evaluation of operational chronic infection endpoints for HCV vaccine trials.

Authors:  Minhee Kang; Uwe Nicolay
Journal:  Contemp Clin Trials       Date:  2008-04-09       Impact factor: 2.226

2.  Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.

Authors:  Ekaterina Alekseeva; Irina Sominskaya; Dace Skrastina; Irina Egorova; Elizaveta Starodubova; Eriks Kushners; Marija Mihailova; Natalia Petrakova; Ruta Bruvere; Tatyana Kozlovskaya; Maria Isaguliants; Paul Pumpens
Journal:  Genet Vaccines Ther       Date:  2009-06-08

3.  Generation of cellular immune responses to HCV NS5 protein through in vivo activation of dendritic cells.

Authors:  P Wintermeyer; S Gehring; A Eken; J R Wands
Journal:  J Viral Hepat       Date:  2010-10       Impact factor: 3.728
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.